TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02781688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
Study: NCT04419077

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality exposure
Description: Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content.
Study: NCT05764434

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
Study: NCT00808015

Intervention type: DRUG
Intervention: varenicline
Description: Champix will be prescribed as per usual practice and at the sole discretion of the physician
Study: NCT01397656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPR using 30:2 ratio
Description: Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPR using continuous compressions
Description: Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
Study: NCT02993016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient-specific instruments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Signature™ Vanguard

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional instruments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard PS(posterior stabilized)
Study: NCT02636166

Intervention type: OTHER
Group type: OTHER
Intervention: Clearblue Investigational Pregnancy test
Description: Clearblue Investigational Pregnancy test

Intervention type: OTHER
Group type: OTHER
Intervention: Professional pregnancy test
Description: Alere Professional use pregnancy test

Intervention type: OTHER
Group type: OTHER
Intervention: Clearblue Marketed Pregnancy test
Description: Clearblue Marketed Pregnancy test
Study: NCT01819389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib and Nilotinib
Study: NCT00479739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate or formoterol/budesonide
Study: NCT00514709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB PRP~T Combined Vaccine
Description: 0.5 mL, Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: Oral co-administered with study vaccine.
Study: NCT03105089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic preconditioning
Description: ) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
Study: NCT01071083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab
Description: 300 mg intravenous every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta 1-a
Description: 30 ug intramuscular once per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1000 mg intravenous every 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: placebo intravenous every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: 20 mg subcutaneous once daily
Study: NCT02469675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: One TMS pulse every 10 seconds for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Description: One median nerve pulse every 10 seconds for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical transcutaneous stimulation
Description: One cervical pulse every 10 seconds for 20 minutes
Study: NCT01095029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim II - 3058
Description: Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim II - 3058
Description: Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim II - 3058
Description: Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
Study: NCT02515981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NH Medicaid Incentives Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NH Medicaid Incentives Program
Study: NCT00303134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet Cell Transplantation
Description: Islet Cell Transplantation for patients with type 1 diabetes mellitus
Study: NCT00665704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website
Description: Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
Study: NCT01855321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
Study: NCT02751255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
Study: NCT03650179

Intervention type: OTHER
Intervention: Observational study : No intervention
Description: Observational study : No intervention. Only exporting data
Study: NCT03029000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim
Description: solution for subcutaneous injection
Study: NCT03667586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Description: Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group cognitive behavioral therapy
Description: Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
Study: NCT00185731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg orally once daily
Study: NCT04720885

Intervention type: PROCEDURE
Intervention: kind of surgery
Description: hysteroscopy, curettage, other
Study: NCT02232685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-Choline PET/CT
Description: 18F-Choline PET/CT
Study: NCT01385501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video intervention along with educational hand out
Description: The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
Study: NCT02200614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 2 tablets twice daily with food.
Study: NCT01465074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex
Description: 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum
Description: 30 min chewing, one dose
Study: NCT04252040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
Study: NCT01287585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
Description: 18 mg/m2, weekly, intramuscular, until disease progression or toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly, intramuscular, until disease progression or toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: treatment of disease-related symptoms throughout the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: treatment of disease-related symptoms throughout the study.
Study: NCT04010565

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
Study: NCT04526028

Intervention type: DRUG
Intervention: Fulvestrant Injectable Product
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.

Intervention type: DRUG
Intervention: Fulvestrant Injectable Product
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
Study: NCT01465412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
Study: NCT02257346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
Study: NCT02817763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft (CTG)
Description: Periodontal surgical technique to treat gingival recessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG plus resin composite restoration
Description: Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium dipyrone
Description: sodium dipyrone was recommended for all participants after the surgical procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium dipyrone
Description: sodium dipyrone was recommended for all participants after the surgical procedures.
Study: NCT02701465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise: local high intensity interval exercise
Description: The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise: best clinical practice
Description: The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Pill
Description: Ketoconazole pill is taken 4 times per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per Inpatient Stay
Study: NCT03196921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encochleated Amphotericin B
Description: lipid-crystal nanoparticle formulation of amphotericin B; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encochleated Amphotericin B
Description: lipid-crystal nanoparticle formulation of amphotericin B; oral
Study: NCT00687258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitabranE ViE
Description: Polysulfone dialyser with vitamin E alpha-tocopherol
Study: NCT02688634

Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
Study: NCT03120975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized decision support and audit & feedback
Description: * suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit & Feedback
Description: \* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard antibiotic stewardship
Description: * Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic stewardship
Description: * Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)
Study: NCT03219528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 mg three times daily for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Low FODMAP dietary intervention for 4 weeks
Study: NCT01354821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular aortic repair
Description: Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open surgical repair
Description: Conventional therapy in France with the national database of the M.O.H.
Study: NCT05917730

Intervention type: BEHAVIORAL
Intervention: Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)
Description: Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell.
Study: NCT01754714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 1000 mg
Description: 1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
Study: NCT01094574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
Study: NCT00134680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
Study: NCT01731119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latuda©
Description: All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Pills is taken twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Injection
Description: Dexamethasone IV injection is given twice per Inpatient Stay
Study: NCT01754714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 1500 mg
Description: 1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
Study: NCT02600936

Intervention type: DEVICE
Intervention: vein stent placement
Description: Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
Study: NCT03481972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline and tauroursodeoxycholic acid
Description: doxycicline and tauroursodeoxycholic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT02885220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Program
Description: No scheduled intermediate weight loss goals provided to patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed Program
Description: Scheduled program with intermediate weight loss targets reinforced to patients during follow up.